Oral antibiotics with antiinflammatory/immunomodulatory effects in the treatment of various dermatoses;Orale antibiotika mit antiinflammatorischer/immunmoduiatorischer wirkung für die therapie verschiedener dermatosen

Hautarzt

Volumn 53, Issue 7, 2002, Pages 456-465

  Brinkmeier, T ^a   Frosch, P J ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Antibiotics; Immunomodulation; Macrolides; Structure activity relationships; Tetracylines

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CYTOKINE; IMMUNOLOGICAL ADJUVANT; STEROID; ANTIBIOTIC AGENT; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLOBETASOL; DOXYCYCLINE; ERYTHROMYCIN; MACROLIDE; METHYLPREDNISOLONE; METRONIDAZOLE; MINOCYCLINE; NICOTINAMIDE; PREDNISONE; ROXITHROMYCIN; TETRACYCLINE;

AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; IMMUNOLOGY; METABOLISM; ORAL DRUG ADMINISTRATION; REVIEW; SKIN DISEASE; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; ANTIBIOTIC THERAPY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS HERPETIFORMIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG STRUCTURE; IMMUNOMODULATION; LEUKOCYTOCLASTIC VASCULITIS; LICHEN PLANUS; LUPUS ERYTHEMATOSUS; PAPILLOMATOSIS; PEMPHIGOID; PEMPHIGUS VULGARIS; PITYRIASIS ROSEA; PRURIGO; PUSTULOSIS PALMOPLANTARIS; SARCOIDOSIS; SCLERODERMA; SKIN LUPUS ERYTHEMATOSUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CLINICAL TRIALS; CYTOKINES; HUMANS; IMMUNITY, CELLULAR; SKIN DISEASES; STEROIDS; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 0036882092     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-001-0334-4     Document Type: Review

References (63)

1. Schubert S, Andresen BH, Bähr V et al. (1996) The immunomodulatory effects of antibiotics: in vitro and ex vivo investigations of 21 substances by means of the lymphocyte transformation test. Zbl Bakt 284:402-438
2. Van Vlem B, Vanholder R, De Paepe P, Vogelaers D, Ringoir S (1996) The immunomodulatory effects of antibiotics: literature review Infection 24:275-291
3. Labro MT (2000) Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? Clin Microbiol Rev 13:615-650
4. Thong YH (1982) Immunomodulation by antimicrobial drugs. Med Hypotheses 8:361-370
5. Roszkowski W, Ko HL, Roszkowski K, Jeljaszewicz J, Pulverer G (1985) Antibiotics and immunomodulation: effects of cefotaxime, amicacin, mezlocillin, piperacillin and clindamycin. Med Microbiol Immunol 173:279-289
6. Labro MT (1998) Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 41 [Suppl B]:37-46
7. Wales D, Woodhead M (1999) The antiinflammatory effects of macrolides. Thorax 54 [Suppl 2]:58-62
8. Tamaoki J, Kondo M, Kohri K, Aoshiba K, Tagaya E, Nagai A (1999) Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J Immunol 163:2909-2915
9. Ianaro A, Ialenti A, Maffia P et al. (2000) Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 292:156-163
10. Kohyama T, Takizawa H, Kawasaki S, Akiyama N, Sato M, Ito K (1999) Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. Antimicrob Agents Chemother 43:907-911
11. Aoshiba K, Nagai A, Konno K (1995) Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother 39:872-877
12. Sharma PK, Yadav TP, Gautam RK, Taneja N, Satyanarayana L (2000) Erythromycin in pityriasis rosea: a double-blind, placebo-controlled clinical trial. J Am Acad Dermatol 42:241-244
13. Komine M, Tamaki K (2000) An open trial of oral macrolide treatment for psoriasis vulgaris. J Dermatol 27:508-512
14. Tamaki K (2000) Anti-pruritic effect of macrolide antibiotics. J Dermatol 27:66-67
15. Truhan AP, Hebert AA, Esterly NB (1986) Pityriasis lichenoides in children: therapeutic response to erythromycin. J Am Acad Dermatol 15:66-70
16. Altomare G, Capella GL, Fracchiolla C, Frigerio E (1999) Treatment of bullous pemphigoid with erythromycin: a reappraisal. Eur J Dermatol 9:583-585
17. Mensing H, Brehm H, Nasemann T (1984) Bullöses Pemphigoid im Kindesalter. Hautarzt 35:254-258
18. Mensing H, Krauße S (1990) Therapie des bullösen Pemphigoids mit Erythromycin. Med Klin 85:481-484
19. Shapiro LE, Knowles SR, Shear NH (1997) Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 133:1224-1230
20. Ozog DM, Gogstetter DS, Scott G, Gaspari AA (2000) Minocycline-induced hyperpigmentation in patients with pemphigus and pemphigoid. Arch Dermatol 136:1133-1138
21. Ghate JV, Turner ML, Rudek MA et al. (2001) Drug-induced lupus associated with COL-3. Arch Dermatol 137:471-474
22. Humbert P, Treffel P, Chapuis JF (1991) The tetracyclines in dermatology. J Am Acad Dermatol 25:691-697
23. Webster GF, Toso SM, Hegemann L (1994) Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin: involvement of protein kinase C. Arch Dermatol 130:748-752
24. Sainte-Marie I, Tenaud I, Jumbou O, Dreno B (1999) Minocycline modulation of alpha-MSH production by keratinocytes in vitro. Acta Derm Venereol 79:265-267
25. Kloppenburg M, Verweij CL, Miltenburg AMM, Verhoeven AJ, Daha MR, Dijkmans BAC, Breedveld FC (1995) The influence of tetracyclines on T cell activation. Clin Exp Dermatol 102:635-641
26. Liu J, Kuszynski CA, Baxter BT (1999) Doxycycline induces Fas/Fas ligand-mediated apoptosis in Jurkat T lymphocytes. Biochem Biophys Res Commun 260:S62-S67
27. Humbert P, Renaud A, Millet J, Taillard C, Marchal F, Laurent R, Agache P (1989) Evaluation of the effect of heparin and tetracycline on the cohesion of the dermal-epidermal junction. Acta Dermatol Venereol 69:434-436
28. Wahl LM, Lampel LL (1987) Regulation of human peripheral blood monocytes collagenase by prostaglandins and anti-inflammatory drugs. Cell Immunol 105:411-422
29. Hornschuh B, Hamm H, Wever S, Hashimoto T, Schröder U, Bröcker EB, Zilikens D (1997) Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol. J Am Acad Dermatol 36:101-103
30. Oikarinen AI, Zone JJ, Ahmed AR, Kiistala U, Uitto J (1983) Demonstration of collagenase and elastase acitivities in the blister fluids from bullous skin diseases. Comparison between dermatitis herpetiformis and bullous pemphigoid. J Invest Dermatol 81:261-266
31. Retief CR, Malkinson FD, Pearson RW (1999) Two cases of epidermolysis bullosa simplex successfully treated with tetracycline. Arch Dermatol 135:997-998
32. White JE (1989) Minocycline for dystrophic epidermolysis bullosa. Lancet 1:966
33. Humbert P, Faivre B, Gibey R, Agache P (1991) Use of anti-collagenase properties of doxycycline in treatment of α1-antitrypsin deficiency panniculitis. Acta Derm Venereol 71:189-194
34. Chng WJ, Henderson CA (2001) Suppurative panniculitis associated with alpha 1-antitrypsin deficiency (PiSZ phenotype) treated with doxycycline. Br J Dermatol 144:1282-1283
35. Piamphongsant T (1974) Tetracycline for the treatment of pityriasis lichenoides. Br J Dermatol 91:319-322
36. Thomsen K, Osterbye P (1973) Pustulosis palmaris et plantaris. Br J Dermatol 89:293-296
37. Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L (2001) The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 137:69-73
38. Aso M, Miyamoto T, Morimura T, Shimao S (1989) Prurigo pigmentosa successfully treated with minocycline. Br J Dermatol 120:705-708
39. Rabenhorst S, Dreier B, Metze D, Hildebrand A, Frosch PJ (1997) Prurigo pigmentosa. Hautarzt 48:406-409
40. Aramaki J, Happle R (2001) Prurigo pigmentosa. Hautarzt 52:111-115
41. Montemarano AD, Hengge M, Sau P, Welch M (1996) Confluent and reticulated papillomatosis: response to minocycline. J Am Acad Dermatol 34:253-256
42. Le CH, Morales A, Trentham DE (1998) Minocycline in early diffuse scleroderma. Lancet 352:1755-1756
43. Calebotta A, Saenz AM, Gonzalez F, Carvalho M, Castillo R (1999) Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients. Int J Dermatol 38:217-221
44. Chaffins ML, Collison D, Fivenson DP (1993) Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol 28:998-1000
45. Gaspar ZS, Walkden V, Wojnarowska F (1996) Minocycline is a useful adjuvant therapy for pemphigus. Australas J Dermatol 37:93-95
46. Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D (1994) Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 130:753-758
47. Lamp KC, Freeman CD, Klutman NE, Lacy MK (1999) Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 36:353-373
48. Stranz MH, Bradley WE (1981) Metronidazole (Flagy IV, Searle). Drug Intell Clin Pharm 15:838-846
49. Kapoor K, Chandra M, Nag D, Paliwal JK, Gupta RC, Saxena RC (1999) Evaluation of metronidazole toxicity: a prospective study. Int J Clin Pharmacol Res 19:83-88
50. Grove DI, Mahmound AA, Warren KS (1977) Suppression of cell-mediated immunity by metronidazole. Int Arch Allergy Appl Immunol 54:422-427
51. Duhra P, Paul CJ (1988) Metastatic Crohn's disease responding to metronidazole. Br J Dermatol 119:87-91
52. Kano Y, Shiohara T, Yagita A, Nagashima M (1992) Treatment of recalcitrant cheilitis granulomatosa with metronidazole. J Am Acad Dermatol 27:629-630
53. Akamatsu H, Oguchi M, Nishijima S, Asada Y, Takahashi M, Ushijima T, Niwa Y (1990) The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res 282:449-454
54. Braun-Falco O, Korting HC (1983) Metronidazoltherapie bei Rosazea. Hautarzt 34:261-265
55. Büyük AY, Kavala M (2000) Oral metronidazole treatment of lichen planus. J Am Acad Dermatol 43:260-262
56. Manzella JP, Clark JK (1983) Effects of moxalactam and cefuroxime on mitogen-stimulated human mononuclear leukocytes. Antimicrob Agents Chemother 23:360-363
57. Perry CM, Brogden RN (1996) Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 52:125-158
58. Rudnicka L, Szymanska E, Walecka I, Slowinska M (2000) Long-term cefuroxime axetil in subacute cutaneous lupus erythematosus. A report of three cases. Dermatology 200:129-131
59. Plewig G, Schöpf E (1975) Anti-inflammatory effects of antimicrobial agents: an in vivo study. J Invest Dermatol 65:532-536
60. Anderegg U, Wilczek A, Haustein UF (2000) Penicillin G does not alter collagen type I metabolism of dermal fibroblasts in culture. Dermatology 200:111-114
61. Zirbel GM, Gellis SE, Kadin ME, Esterly NB (1995) Lymphomatoid papulosis in children. J Am Acad Dermatol 33:741-748
62. Liu Y, Ramamurthy NS, Lee HM et al (2001) The lipophilicity, pharmacokinetics, and cellular uptake of different chemically- modified tetracyclines (CMTs). Curr Med Chem 8:243-252
63. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR (1991) Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 2:297-321